Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Objective Tapering of selective serotonin reuptake inhibitor (SSRI) therapy, as opposed to abrupt discontinuation, has been recommended by several guidelines and in the literature in order to diminish the occurrence of discontinuation symptoms. However, the evidence of a favourable effect of tapering is limited, and it is unclear how patients ought to discontinue SSRIs in daily life. The aim of this study was to examine the way in which patients discontinue SSRI therapy in clinical practice and to compare the effect of tapering with that of abrupt discontinuation on the occurrence of discontinuation symptoms. Methods Patients (n = 74) who recently discontinued SSRI therapy completed a questionnaire containing questions about discontinuation symptoms (DESS events), the prescribed SSRI, reasons for discontinuation, way of discontinuation, knowledge of discontinuation symptoms, impact on daily life and patient counseling and education. The number of DESS events was compared among groups (abrupt discontinuation versus tapering; age; male versus female; paroxetine versus other SSRIs; knowledge of discontinuation symptoms at start of therapy versus lack of knowledge). Results A total of 66 patients were eligible for analysis. Of all patients ending SSRI therapy, 21% abruptly discontinued therapy. There was a significant difference in the number of DESS events between abrupt discontinuation and tapering of SSRI therapy (12.0 versus 5.9). There was also a tendency for an adverse effe…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one study (n = 74), participants who tapered their SSRI dose over a period of up to four months had significantly fewer withdrawal symptoms compared to patients who discontinued abruptly (van Geffen 2005).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as van Geffen 2005
In the citing paper
“Reduction of paroxetine by 10mg every 2 weeks, lowered withdrawal incidence from 34% to 4.6%, when compared with abrupt discontinuation in one study 34 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [34]
In the citing paper
“About 16% of patients taking paroxetine versus 6% of those receiving fluoxetine reported discontinuation symptoms (p < 0.05).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [38]
In the citing paper
“During discontinuation, the paroxetine treatment group also reported significant increases in depressive symptoms and clinical global severity scores as well as difficulty in social functioning.”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [38]
In the citing paper
“In conclusion, among patients with MDD, the average mean DESS score was 5.7 (SD = 7.36) for those who discontinued treatment with paroxetine [22,38,39,45] , whereas for escitalopram [41,45] it ranged from 2.4 to 3.2, and in both studies investigating fluoxetine discontinuation [22,38] , it was 0.2 (SD = 3.86).”
From Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review (2015) · cites this paper as [38]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · cited 2×
“Patients were classified as having experienced a ‘‘discontinuation syndrome’’ if the number of reported DESS events increased by four or more from during treatment to the week after discontinuation of treatment [ 14 ].”
BackgroundMethodBull, S. A., Hu, X. H., Hunkeler, E. M., Lee, J. Y., Ming, E. E., Markson, L. E., & Fireman, B. (2002) · JAMA · doi:10.1001/jama.288.11.1403 · Cited by 359 · cited 1×
“remember being told have also been shown [13].”
BackgroundAnderson, I. M., Nutt, D. J., & Deakin, J. F. W. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400101 · Cited by 310
Study of Compulsive Buying in Depressed Patients
Lejoyeux, M., Tassain, V., Solomon, J., & AdAs, J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0406 · Cited by 271
Antidepressant Discontinuation Syndromes: Clinical Relevance, Prevention and Management
Haddad, P. M. (2001) · Drug Safety · doi:10.2165/00002018-200124030-00003 · Cited by 214 · cited 1×
“... stop therapy with selective serotonin reuptake inhibitors (SSRIs) discontinuation symptoms occur, which can be bothersome, have an adverse effect on patients’ quality of life and may lead to unnecessary renewed antidepressant use [1, 2]. In some patients, these discontinuation symptoms can even cause considerable…”
BackgroundDemyttenaere, K., Enzlin, P., Dewé, W., Boulanger, B., Bie, J. D., Troyer, W. D., & Mesters, P. (2001) · PubMed · Cited by 204
PRICE, J. S., WALLER, P. C., WOOD, S. M., & MACKAY, A. V. P. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.00498.x · Cited by 171 · cited 3×
“In some patients, these discontinuation symptoms can even cause considerable morbidity, can be misdiagnosed leading to inappropriate treatment and can adversely affect future antidepressant compliance [3, 4].”
BackgroundResultIn vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
Bymaster, F. P., Rasmussen, K. G., Calligaro, D. O., NELSON, D. A., DeLapp, N. W., Wong, D. T., & Moore, N. A. (1997) · PubMed · Cited by 162
Antidepressant discontinuation syndromes
Haddad, P. M., Anderson, I., & Rosenbaum, J. (2004) · Adverse Syndromes and Psychiatric Drugs · doi:10.1093/med/9780198527480.003.0010 · Cited by 160
Research works printed but not linked: 1
- Young AH, Currie A (1997) Physicians’ knowledge of antidepressant withdrawal effects: a survey. J Clin Psychiatry 58:28–30
Cited by
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Cutler, A. J., Montgomery, S. A., Feifel, D., Lazarus, A., Åström, M., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04592 · Cited by 137
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123
Metadata
- Authors
- van Geffen, E. C. G., Hugtenburg, J. G., Heerdink, E. R., van Hulten, R. P., & Egberts, A. C. G.
- Affiliations
- Utrecht University (NL)
- Corresponding author
- Heerdink, E. R.
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2005-05-20
- Volume
- 61
- Issue
- 4
- Pages
- 303-307
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2060456881
- Semantic Scholar
- 3ff04104d6384092e4f35f7d1ecea018ac5b6979
- Cited by
- 72
- References
- 20
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 3 · 2023: 5 · 2022: 3 · 2021: 4 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 1 · 2012: 5
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
- dspace.library.uu.nl
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- selective serotonin reuptake inhibitors, SSRI discontinuation, withdrawal symptoms, tapering, abrupt discontinuation, paroxetine, reasons for discontinuation, patient counseling
- MeSH terms
- Adult, Depression, Female, Fluoxetine, Humans, Male, Middle Aged, Netherlands, Quality of Life, Surveys and Questionnaires, Substance Withdrawal Syndrome, Time Factors, Citalopram, Selective Serotonin Reuptake Inhibitors, Paroxetine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. https://app.cochat.ai/papers/10.1007/s00228-005-0921-x
- The paper
- van Geffen, E. C. G., Hugtenburg, J. G., Heerdink, E. R., van Hulten, R. P., & Egberts, A. C. G. (2005). Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-005-0921-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.